(Q38067424)

28 August 2017

1 reference

title

Insulin degludec: overview of a novel ultra long-acting basal insulin (English)

1 reference

28 August 2017

1 reference

4

1 reference

28 August 2017

S C L Gough

1

1 reference

28 August 2017

S Harris

series ordinal

2

1 reference

28 August 2017

V Woo

series ordinal

3

1 reference

28 August 2017

publication date

29 January 2013

1 reference

Diabetes, Obesity and Metabolism

28 August 2017

published in

1 reference

28 August 2017

volume

15

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

301-309

1 reference

New insulins in the treatment of diabetes mellitus

28 August 2017

cites work

1 reference

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

21 January 2018

1 reference

Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections

21 January 2018

1 reference

Insulin analogues and other developments in insulin therapy for diabetes

21 January 2018

1 reference

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes

21 January 2018

1 reference

Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies

21 January 2018

1 reference

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride.

21 January 2018

1 reference

Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes

21 January 2018

1 reference

The Treat-to-Target Trial and related studies

21 January 2018

1 reference

Insulin detemir: A historical perspective on a modern basal insulin analogue

21 January 2018

1 reference

Refining basal insulin therapy: what have we learned in the age of analogues?

21 January 2018

1 reference

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

21 January 2018

1 reference

Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.

21 January 2018

1 reference

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes

21 January 2018

1 reference

A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial

21 January 2018

1 reference

Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial

21 January 2018

1 reference

Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.

21 January 2018

1 reference

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)

21 January 2018

1 reference

Hypoglycemia in insulin-treated diabetes: a case for increased vigilance

21 January 2018

1 reference

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial

21 January 2018

1 reference

The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin

21 January 2018

1 reference

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12052

1 reference

28 August 2017

1 reference